Global University Venturing

Neurodegenerative disease company Transquis has emerged from stealth with $30m in series A funding to advance research conducted at Stanford.

Eir’s first fund will partner Nordics-based universities to invest in their spinouts, while also making selected deals in the rest of Europe and the US.

An unnamed endowment is among the LPs in Engineering Capital's third fund, which is aligned to the innovation pipelines at Stanford, Michigan and Toronto.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Zhejiang University Future Capital-backed cancer and inflammatory disease drug developer has now raised more than $260m in under two years.

University of Birmingham‘s infectious disease reagent producer Native Antigen Company has been acquired in a deal enabling Mercia Asset Management to exit.

The female entrepreneur-focused social impact firm, which mainly invests at series A and B stage, secured university endowments as LPs for its second fund.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Chalmers Ventures head of startups Stina Linge will leave on September 2 to head up Lipidor's animal health products unit Emollivet.

Lundbeckfonden Ventures took a board seat at Leiden spinout VarmX as part of a round that will fund development of a treatment for spontaneous bleeding.

Sodium-ion battery producer Natron, a Stanford spinout, has picked up corporates ABB and Chevron in a round bringing its lifetime funding to more than $70m.